XtalPi, an AI drug discovery company and subsidiary of Ailux Biologics, has entered a licensing agreement with Janssen Biotech, a Johnson & Johnson company, to utilise its proprietary AI biologics discovery platform, XtalFold.
The agreement, facilitated by Johnson & Johnson Innovation, provides Janssen and its affiliates a non-exclusive licence to utilise the platform for the discovery and development of biologics.
XtalFold is an AI-based software suite that delivers fast and precise structural insights, aiding biologics innovation across various phases.
The platform uses sequence information to model biomolecule interactions, which are crucial for biotherapeutics such as monoclonal antibodies.
In benchmark studies, XtalFold has demonstrated robust performance, especially in the overall success rate and modelling of complex regions such as the antibody-antigen interface.
XtalFold has been validated in more than 30 partner and internal programmes since its launch in 2023. It has shown significant results in applications including antigen design, epitope identification, affinity maturation, pH-sensitivity engineering and bispecifics design.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
XtalPi vice-president and Ailux Biologics head Alex Li stated: “Biologics are intricate machines that operate in three-dimensional space. XtalFold enables the visualisation and design of biologics in 3D space in real-time, which could take months using currently available experimental approaches.
“We are excited to share with Janssen this foundational technology, which has already proven transformative in-house.”
In May 2023, XtalPi announced a $250m AI drug discovery collaboration with Eli Lilly, aimed at the design and delivery of drug candidates using Xtalpi’s AI drug discovery solution.
